Great Basin Scientific Inc. (fka GBSNQ)

[Atlanta1]

and do the losses diminish as more tests are used, more often?

do the losses diminish as more cost control initiatives are executed?

do you expect R&D costs to diminish as more tests are approved and brought on line as part of the expanding portfolio?

are there any additional tests in the pipeline pending additional FDA approvals?

is there a huge market for these cost-efficient tests that GBSN is now pursuing, especially in an environment where there is a focus on controlling the soaring cost of healthcare?

has the debt come down drastically?

have timid investors/traders missed the beginning of yet another trading opportunity?

does a focus on the rear view mirror prevent timid investors/traders, previously burned, from seeing clearly ahead?

$GBSN